Targeting PI3K Signaling in Acute Lymphoblastic Leukemia

摘要: Adhesion of acute lymphoblastic leukemia (ALL) cells to bone marrow stroma triggers intracellular signals regulating cell-adhesion-mediated drug resistance (CAM-DR). Stromal cell protection ALL has been shown require active AKT. In chronic lymphocytic (CLL), adhesion-mediated activation the PI3K/AKT pathway is reported. A novel FDA-approved PI3Kδ inhibitor, CAL-101/idelalisib, leads downregulation p-AKT and increased apoptosis CLL cells. Recently, two additional PI3K inhibitors have received FDA approval. As also implicated in survival cells, evaluated preclinically ALL. However, inhibition yet be approved for clinical use Here, we review role normal hematopoietic We focus on summarizing targeting strategies